Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric ADHD drug safety

Executive Summary

FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder drugs at a March 22 meeting. The meeting is a continuation of the discussion begun at a June 2005 meeting. At that time, the committee discouraged labeling changes to Johnson & Johnson's Concerta and other methylphenidate products to address psychiatric and cardiovascular events (1"The Pink Sheet" July 4, 2005, p. 3). The pediatric meeting will follow a Feb. 9 meeting of FDA's Drug Safety & Risk Management Advisory Committee on ADHD drug cardiovascular safety (2"The Pink Sheet" Jan. 9, 2006, In Brief). The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...

You may also be interested in...

Concerta Adverse Events Update On “Drug Watch” Web Site Advised By Cmte.

FDA should consider posting concerns about psychiatric and cardiovascular adverse events with Johnson & Johnson's Concerta and other methylphenidate products on the agency's upcoming "Drug Watch" website, members of FDA's Pediatric Advisory Committee said

EU MDR Notified Body Designations Could Soar By A Third By End 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.

Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts